153:@0.890196:0.957873:0.914685:0.957873:0.914685:0.938882:0.890196:0.938882:0.007305:0.008593:0.008591
6:@0.941813:0.497523:0.963291:0.497523:0.963291:0.450045:0.941813:0.450045:0.021478
TARGETED LONG-READ SEQUENCING PROVIDES PERSONALIZED BIOMARKERS FOR:@0.410650:0.057372:0.882354:0.057372:0.882354:0.040253:0.410650:0.040253:0.005566:0.007919:0.008311:0.008404:0.006985:0.006387:0.006985:0.008423:0.002988:0.006481:0.008442:0.008759:0.008404:0.005155:0.008423:0.006985:0.007919:0.008423:0.002988:0.007807:0.006985:0.008442:0.008367:0.006985:0.008759:0.008255:0.003511:0.008759:0.008404:0.002988:0.008050:0.008307:0.008330:0.007620:0.003511:0.008423:0.006871:0.007807:0.002988:0.008050:0.006985:0.008348:0.007807:0.008442:0.008759:0.007919:0.006481:0.003511:0.006630:0.006985:0.008423:0.002988:0.008236:0.003511:0.008442:0.011112:0.007919:0.008423:0.008031:0.006985:0.008347:0.007807:0.002988:0.006593:0.008442:0.008423
MINIMAL RESIDUAL DISEASE TRACING IN PEDIATRIC LEUKEMIA:@0.521755:0.073247:0.882541:0.073247:0.882541:0.056128:0.521755:0.056128:0.011112:0.003511:0.008759:0.003511:0.011112:0.007919:0.006292:0.002988:0.008423:0.006873:0.007807:0.003511:0.008423:0.008255:0.007919:0.006294:0.002988:0.008423:0.003511:0.007807:0.006985:0.007712:0.007807:0.006985:0.002988:0.006387:0.008423:0.007863:0.008255:0.003511:0.008759:0.008404:0.002988:0.003511:0.008759:0.002988:0.008050:0.006985:0.008423:0.003511:0.007095:0.006387:0.008423:0.003511:0.008255:0.002988:0.006481:0.006985:0.008367:0.008031:0.006985:0.011112:0.003511:0.007919
to guide sequencing to the 7.7 kb region within TAL1 and one crRNA to cover the 3.7 kb :@0.147059:0.121273:0.886398:0.121273:0.886398:0.100900:0.147059:0.100900:0.006209:0.011048:0.003789:0.009861:0.011413:0.005547:0.011322:0.009039:0.003789:0.007875:0.009106:0.010706:0.011345:0.009039:0.011598:0.008994:0.005615:0.011459:0.009861:0.003789:0.006209:0.011048:0.003789:0.006620:0.011299:0.009039:0.003789:0.010432:0.004497:0.010432:0.003789:0.010274:0.011025:0.003789:0.007442:0.009039:0.009861:0.005547:0.010843:0.011756:0.003789:0.014723:0.005273:0.006620:0.011459:0.005615:0.011756:0.003789:0.011710:0.014929:0.011619:0.010432:0.003789:0.009085:0.011596:0.011391:0.003789:0.010843:0.011596:0.009039:0.003789:0.008994:0.007807:0.013376:0.015408:0.014929:0.003789:0.006209:0.011048:0.003789:0.008994:0.010866:0.009633:0.009039:0.007807:0.003789:0.006620:0.011299:0.009039:0.003789:0.010432:0.004497:0.010432:0.003789:0.010272:0.011025:0.004109
region within SIL (:@0.147059:0.141852:0.304904:0.141852:0.304904:0.121479:0.147059:0.121479:0.007442:0.009039:0.009861:0.005547:0.010843:0.011756:0.004109:0.014723:0.005273:0.006620:0.011459:0.005615:0.011756:0.004109:0.009768:0.007259:0.011619:0.004109:0.006939
Figure 1C:@0.304903:0.141852:0.392787:0.141852:0.392787:0.120719:0.304903:0.120719:0.011596:0.006209:0.010751:0.011893:0.008263:0.009473:0.004018:0.010911:0.014769
).:@0.392785:0.141852:0.404222:0.141852:0.404222:0.121479:0.392785:0.121479:0.006939:0.004497
KMT2A and SIL-TAL1 detection:@0.147059:0.181656:0.392315:0.181656:0.392315:0.158496:0.147059:0.158496:0.010708:0.014817:0.008541:0.009861:0.010309:0.003735:0.010558:0.011679:0.011231:0.003984:0.010409:0.004856:0.007443:0.005877:0.007520:0.010558:0.008068:0.005229:0.003984:0.011231:0.009363:0.008616:0.009363:0.010907:0.008616:0.004856:0.011256:0.011679
To validate our assay design, we sequenced ten acute lymphoblastic leukemia samples: :@0.147059:0.232398:0.886462:0.232398:0.886462:0.212025:0.147059:0.212025:0.010866:0.011048:0.005510:0.009838:0.009405:0.005250:0.005547:0.011573:0.008811:0.006209:0.009039:0.005513:0.010820:0.011413:0.007807:0.005510:0.009291:0.007533:0.007944:0.008925:0.009724:0.005513:0.011322:0.009039:0.007601:0.005615:0.009861:0.011756:0.004497:0.005510:0.014518:0.009039:0.005513:0.007875:0.009108:0.010706:0.011345:0.009039:0.011596:0.008994:0.009108:0.011391:0.005510:0.006209:0.009039:0.011756:0.005513:0.009291:0.009108:0.011071:0.006209:0.009039:0.005510:0.005182:0.009724:0.017280:0.011162:0.011299:0.010957:0.010911:0.005433:0.009291:0.007510:0.006437:0.005547:0.008994:0.005513:0.005182:0.009131:0.011550:0.010272:0.009039:0.017645:0.005798:0.009291:0.005510:0.007944:0.009085:0.017280:0.011162:0.005182:0.009039:0.007670:0.004497:0.004109
five B-ALL (B-ALL1, B-ALL2, B-ALL3, B-ALL4, and B-ALL5) and five T-ALL (T-ALL1, :@0.147059:0.252977:0.886532:0.252977:0.886532:0.232604:0.147059:0.232604:0.005684:0.005615:0.009633:0.009039:0.003675:0.012646:0.007533:0.014929:0.011619:0.011619:0.003675:0.006939:0.012646:0.007533:0.014929:0.011619:0.011619:0.010432:0.004497:0.003675:0.012646:0.007533:0.014929:0.011619:0.011619:0.010432:0.004497:0.003675:0.012646:0.007533:0.014929:0.011619:0.011619:0.010432:0.004497:0.003675:0.012646:0.007533:0.014929:0.011619:0.011619:0.010432:0.004497:0.003675:0.009085:0.011596:0.011391:0.003675:0.012646:0.007533:0.014929:0.011619:0.011619:0.010432:0.006939:0.003675:0.009085:0.011596:0.011391:0.003675:0.005684:0.005615:0.009633:0.009039:0.003675:0.011801:0.007533:0.014929:0.011619:0.011619:0.003675:0.006825:0.011801:0.007533:0.014929:0.011619:0.011619:0.010432:0.004497:0.004109
T-ALL2, T-ALL3, T-ALL4, and T-ALL5). For the B-ALL1 and B-ALL2 samples, previ-:@0.147059:0.273556:0.882353:0.273556:0.882353:0.253183:0.147059:0.253183:0.011801:0.007533:0.014929:0.011619:0.011619:0.010432:0.004497:0.005273:0.011801:0.007533:0.014929:0.011619:0.011619:0.010432:0.004497:0.005273:0.011801:0.007533:0.014929:0.011619:0.011619:0.010432:0.004497:0.005273:0.009085:0.011596:0.011391:0.005273:0.011801:0.007533:0.014929:0.011619:0.011619:0.010432:0.006939:0.004497:0.005273:0.010683:0.010843:0.007807:0.005273:0.006617:0.011302:0.009039:0.005273:0.012646:0.007533:0.014929:0.011619:0.011619:0.010432:0.005273:0.009085:0.011596:0.011391:0.005273:0.012646:0.007533:0.014929:0.011619:0.011619:0.010432:0.005273:0.007944:0.009085:0.017280:0.011162:0.005182:0.009039:0.007670:0.004497:0.005273:0.011071:0.007442:0.009336:0.009838:0.005567:0.007533
ous diagnostic efforts identified KMT2A-MLLT1 fusions, however, for B-ALL1 the fu-:@0.147059:0.294134:0.882353:0.294134:0.882353:0.273761:0.147059:0.273761:0.010820:0.011413:0.007670:0.005227:0.011391:0.005798:0.009199:0.009861:0.011596:0.010957:0.007510:0.006437:0.005547:0.008994:0.005227:0.009039:0.005969:0.005787:0.010843:0.007967:0.006437:0.007670:0.005227:0.005547:0.011322:0.009039:0.011391:0.006437:0.005615:0.005684:0.005615:0.009108:0.011391:0.005227:0.014541:0.019608:0.013354:0.010432:0.013605:0.007533:0.019608:0.011619:0.010064:0.013354:0.010432:0.005227:0.006369:0.011413:0.007601:0.005547:0.010843:0.011619:0.007670:0.004497:0.005227:0.011302:0.010863:0.014520:0.009334:0.009635:0.009039:0.006252:0.004497:0.005227:0.006026:0.010843:0.007807:0.005227:0.012646:0.007533:0.014929:0.011619:0.011619:0.010432:0.005227:0.006620:0.011299:0.009039:0.005227:0.006366:0.011507:0.007533
sion could only be detected by RNA-sequencing, but could not be validated by PCR. :@0.147059:0.314713:0.886555:0.314713:0.886555:0.294340:0.147059:0.294340:0.007601:0.005547:0.010843:0.011756:0.006437:0.008994:0.010820:0.011550:0.005182:0.011391:0.006437:0.010843:0.011870:0.005182:0.009724:0.006437:0.011254:0.009039:0.006437:0.011322:0.009131:0.006209:0.009108:0.009106:0.006211:0.009106:0.011391:0.006437:0.010843:0.009724:0.006437:0.013376:0.015408:0.013605:0.007533:0.007875:0.009108:0.010706:0.011345:0.009039:0.011596:0.008994:0.005615:0.011459:0.009679:0.004497:0.006437:0.010799:0.011069:0.006437:0.006437:0.008994:0.010820:0.011550:0.005182:0.011391:0.006437:0.011596:0.010822:0.006437:0.006437:0.011254:0.009039:0.006437:0.009838:0.009405:0.005250:0.005547:0.011573:0.008811:0.006209:0.009108:0.011391:0.006437:0.010843:0.009724:0.006437:0.012167:0.014678:0.013696:0.004497:0.004109
For samples B-ALL3, B-ALL4, and B-ALL5 we performed a blinded analysis and did :@0.147059:0.335292:0.886553:0.335292:0.886553:0.314919:0.147059:0.314919:0.010683:0.010843:0.007807:0.006323:0.007944:0.009085:0.017280:0.011162:0.005182:0.009039:0.007670:0.006323:0.012646:0.007533:0.014929:0.011619:0.011619:0.010432:0.004497:0.006323:0.012646:0.007533:0.014929:0.011619:0.011619:0.010432:0.004497:0.006323:0.009085:0.011596:0.011391:0.006323:0.012646:0.007533:0.014929:0.011619:0.011619:0.010432:0.006323:0.014518:0.009039:0.006323:0.011505:0.009039:0.007807:0.006026:0.010843:0.007807:0.017485:0.009108:0.011391:0.006323:0.009291:0.006323:0.010911:0.005250:0.005615:0.011596:0.011322:0.009106:0.011391:0.006323:0.009085:0.011687:0.009405:0.005182:0.009724:0.007601:0.005615:0.007670:0.006323:0.009085:0.011596:0.011391:0.006323:0.011391:0.005547:0.011391:0.004109
not know the fusion partner before our analysis. For all five T-ALL samples SIL-TAL1 :@0.147059:0.355870:0.886510:0.355870:0.886510:0.335498:0.147059:0.335498:0.011596:0.010820:0.006437:0.005524:0.010703:0.011598:0.010866:0.014723:0.005524:0.006620:0.011299:0.009039:0.005524:0.006366:0.011413:0.007601:0.005547:0.010845:0.011756:0.005524:0.011368:0.009085:0.007967:0.006437:0.011596:0.009039:0.007807:0.005524:0.011254:0.009039:0.006026:0.010843:0.007442:0.009039:0.005524:0.010820:0.011413:0.007807:0.005524:0.009085:0.011687:0.009405:0.005182:0.009724:0.007601:0.005615:0.007670:0.004497:0.005524:0.010683:0.010843:0.007807:0.005524:0.009405:0.005387:0.005250:0.005524:0.005684:0.005615:0.009633:0.009039:0.005524:0.011801:0.007533:0.014929:0.011619:0.011619:0.005524:0.007944:0.009085:0.017280:0.011162:0.005182:0.009039:0.007670:0.005524:0.009770:0.007259:0.011391:0.007533:0.011710:0.014929:0.011619:0.010432:0.004109
rearrangements were detected by heteroduplex analysis. :@0.147059:0.376449:0.619206:0.376449:0.619206:0.356076:0.147059:0.356076:0.007442:0.009291:0.009085:0.007807:0.007898:0.009085:0.011459:0.009656:0.009039:0.017485:0.009039:0.011391:0.006437:0.007670:0.004109:0.014518:0.009039:0.007442:0.009039:0.004109:0.011322:0.009131:0.006209:0.009108:0.009108:0.006209:0.009108:0.011391:0.004109:0.010840:0.009724:0.004109:0.011299:0.009131:0.006209:0.009039:0.007442:0.011276:0.011048:0.011071:0.011162:0.005182:0.009108:0.010089:0.004109:0.009085:0.011687:0.009405:0.005182:0.009724:0.007601:0.005615:0.007670:0.004497:0.004109
Gene A:@0.234173:0.438960:0.299270:0.438960:0.299270:0.420692:0.234173:0.420692:0.013896:0.010782:0.011941:0.010782:0.004553:0.013144
Gene B:@0.486700:0.438960:0.550380:0.438960:0.550380:0.420692:0.486700:0.420692:0.013982:0.010782:0.011941:0.010782:0.004553:0.011641
ChrA:@0.154557:0.438960:0.199101:0.438960:0.199101:0.420692:0.154557:0.420692:0.012457:0.011920:0.007023:0.013144
ChrB:@0.398301:0.438960:0.441341:0.438960:0.441341:0.420692:0.398301:0.420692:0.012457:0.011920:0.007023:0.011641
AB:@0.349802:0.498773:0.390286:0.498773:0.390286:0.480504:0.349802:0.480504:0.028844:0.011641
-:@0.368809:0.498773:0.375402:0.498773:0.375402:0.480504:0.368809:0.480504:0.006593
Fusion Gene:@0.194526:0.498773:0.305260:0.498773:0.305260:0.480504:0.194526:0.480504:0.009708:0.011845:0.008516:0.005034:0.011802:0.011931:0.004553:0.013885:0.010771:0.011931:0.010760
Breakpoint junction:@0.282797:0.539838:0.460133:0.539838:0.460133:0.521570:0.282797:0.521570:0.011641:0.006808:0.010760:0.010352:0.010438:0.012220:0.011791:0.005026:0.011920:0.007109:0.004553:0.005219:0.011834:0.011920:0.009901:0.007109:0.005026:0.011791:0.011920
No PCR product:@0.600600:0.438960:0.742841:0.438960:0.742841:0.420692:0.600600:0.420692:0.014132:0.011791:0.004553:0.011426:0.012457:0.011555:0.004553:0.012220:0.006808:0.011791:0.012113:0.011834:0.009899:0.007109
PCR product:@0.600600:0.498780:0.712362:0.498780:0.712362:0.480512:0.600600:0.480512:0.011426:0.012457:0.011555:0.004553:0.012220:0.006806:0.011791:0.012113:0.011834:0.009899:0.007109
A:@0.154563:0.412835:0.167708:0.412835:0.167708:0.394566:0.154563:0.394566:0.013144
8:@0.343856:0.645476:0.353038:0.645476:0.353038:0.630252:0.343856:0.630252:0.009181
7:@0.299388:0.645476:0.308569:0.645476:0.308569:0.630252:0.299388:0.630252:0.009181
9:@0.371343:0.645476:0.380525:0.645476:0.380525:0.630252:0.371343:0.630252:0.009181
10 11:@0.407589:0.645476:0.448048:0.645476:0.448048:0.630252:0.407589:0.630252:0.009181:0.009181:0.003734:0.009181:0.009181
12 1314:@0.478829:0.645476:0.546331:0.645476:0.546331:0.630252:0.478829:0.630252:0.009181:0.009181:0.009990:0.009181:0.011605:0.009181:0.009181
1:@0.257454:0.645476:0.266635:0.645476:0.266635:0.630252:0.257454:0.630252:0.009181
20 21:@0.619213:0.645476:0.665067:0.645476:0.665067:0.630252:0.619213:0.630252:0.009181:0.009181:0.009128:0.009181:0.009181
19:@0.574749:0.645476:0.593111:0.645476:0.593111:0.630252:0.574749:0.630252:0.009181:0.009181
22 23:@0.687489:0.645476:0.727948:0.645476:0.727948:0.630252:0.687489:0.630252:0.009181:0.009181:0.003734:0.009181:0.009181
24:@0.746930:0.645476:0.765293:0.645476:0.765293:0.630252:0.746930:0.630252:0.009181:0.009181
36:@0.788306:0.645476:0.806669:0.645476:0.806669:0.630252:0.788306:0.630252:0.009181:0.009181
Major :@0.392630:0.593394:0.448965:0.593394:0.448965:0.575126:0.392630:0.575126:0.017397:0.010352:0.005219:0.011791:0.007023:0.004553
breakpoint cluster:@0.339346:0.611632:0.502333:0.611632:0.502333:0.593364:0.339346:0.593364:0.012220:0.006808:0.010760:0.010352:0.010438:0.012220:0.011791:0.005026:0.011920:0.007109:0.004553:0.009622:0.005069:0.011834:0.008505:0.006978:0.010760:0.007023
Minor:@0.677073:0.593394:0.730358:0.593394:0.730358:0.575126:0.677073:0.575126:0.017525:0.005026:0.011920:0.011791:0.007023
breakpoint cluster:@0.622264:0.611632:0.785251:0.611632:0.785251:0.593364:0.622264:0.593364:0.012220:0.006808:0.010760:0.010352:0.010438:0.012220:0.011791:0.005026:0.011920:0.007109:0.004553:0.009622:0.005069:0.011834:0.008505:0.006978:0.010760:0.007023
KMT2A:@0.157692:0.647286:0.221222:0.647286:0.221222:0.629018:0.157692:0.629018:0.011641:0.017053:0.010674:0.011018:0.013144
B:@0.155137:0.592345:0.166777:0.592345:0.166777:0.574077:0.155137:0.574077:0.011641
crK-e7:@0.263313:0.592345:0.319969:0.592345:0.319969:0.574077:0.263313:0.574077:0.009622:0.007023:0.011254:0.006980:0.010760:0.011018
crK-e19:@0.539405:0.592345:0.607079:0.592345:0.607079:0.574077:0.539405:0.574077:0.009622:0.007023:0.011254:0.006980:0.010760:0.011018:0.011018
8,8 kb:@0.394152:0.684411:0.447842:0.684411:0.447842:0.666143:0.394152:0.666143:0.011018:0.004446:0.011018:0.004553:0.010436:0.012220
3,6 kb:@0.651626:0.683294:0.705316:0.683294:0.705316:0.665026:0.651626:0.665026:0.011018:0.004446:0.011018:0.004553:0.010436:0.012220
Chr1 :@0.154560:0.792401:0.201530:0.792401:0.201530:0.774133:0.154560:0.774133:0.012457:0.011920:0.007023:0.011018:0.004553
< TAL1:@0.304682:0.792399:0.364517:0.792399:0.364517:0.774131:0.304682:0.774131:0.012800:0.003673:0.009063:0.013144:0.010137:0.011018
< SIL:@0.631950:0.791928:0.675162:0.791928:0.675162:0.773660:0.631950:0.773660:0.012800:0.004553:0.010588:0.005133:0.010137
7,7 kb:@0.374579:0.734385:0.428270:0.734385:0.428270:0.716117:0.374579:0.716117:0.011018:0.004446:0.011018:0.004553:0.010436:0.012220
< SIL-TAL1:@0.434053:0.872334:0.525244:0.872334:0.525244:0.854066:0.434053:0.854066:0.012800:0.004553:0.010588:0.005133:0.009235:0.005520:0.009063:0.013144:0.010137:0.011018
C:@0.154571:0.734380:0.167028:0.734380:0.167028:0.716112:0.154571:0.716112:0.012457
3,7 kb:@0.780370:0.756726:0.834063:0.756726:0.834063:0.738458:0.780370:0.738458:0.011018:0.004446:0.011018:0.004553:0.010438:0.012220
Figure 1. Schematic outline of fusion genes and the respective crRNA design (A) :@0.147059:0.905157:0.745395:0.905157:0.745395:0.887867:0.147059:0.887867:0.009488:0.005080:0.008797:0.009730:0.006761:0.007751:0.004847:0.008927:0.004445:0.004847:0.008927:0.007433:0.009637:0.007583:0.014810:0.007807:0.005752:0.005155:0.007527:0.004847:0.009338:0.009730:0.005939:0.004781:0.005080:0.009955:0.007751:0.004847:0.009264:0.005678:0.004847:0.005584:0.009674:0.006462:0.005155:0.009264:0.009955:0.004847:0.008423:0.007583:0.009955:0.007751:0.006574:0.004847:0.007900:0.009955:0.009712:0.004847:0.005939:0.009637:0.007751:0.004847:0.006761:0.007751:0.006574:0.009880:0.007956:0.007639:0.005752:0.005248:0.007863:0.007751:0.004847:0.007527:0.007022:0.011579:0.012233:0.012345:0.004847:0.009786:0.007751:0.006462:0.005080:0.008757:0.009955:0.004847:0.006238:0.012345:0.006238:0.003287
Schematic outline :@0.746956:0.905541:0.886596:0.905541:0.886596:0.887695:0.746956:0.887695:0.009114:0.007788:0.009899:0.007937:0.015240:0.007844:0.005788:0.005005:0.007900:0.006257:0.009320:0.009691:0.005808:0.004725:0.005005:0.010141:0.007937:0.004240
of fusion gene formation. Gene A and Gene B are fused together and provide a unique breakpoint :@0.147059:0.920093:0.886680:0.920093:0.886680:0.902247:0.147059:0.902247:0.009301:0.005528:0.004800:0.005640:0.009861:0.006854:0.005005:0.009301:0.010216:0.004800:0.008591:0.007937:0.010141:0.007937:0.004800:0.005360:0.009301:0.007041:0.015240:0.007844:0.005788:0.005005:0.009301:0.010216:0.004258:0.004800:0.013501:0.007937:0.010141:0.007937:0.004800:0.012905:0.004800:0.008031:0.010141:0.009861:0.004800:0.013503:0.007937:0.010141:0.007937:0.004800:0.010982:0.004800:0.008031:0.006686:0.007937:0.004800:0.005640:0.009861:0.007004:0.008031:0.009861:0.004800:0.005584:0.009525:0.008591:0.007937:0.005808:0.009899:0.007937:0.006929:0.004800:0.008033:0.010141:0.009861:0.004800:0.009562:0.006686:0.009226:0.008703:0.005005:0.009861:0.007937:0.004800:0.008199:0.004800:0.009917:0.010216:0.005005:0.009357:0.009917:0.007937:0.004800:0.009264:0.006686:0.008048:0.008292:0.009021:0.009955:0.009301:0.005005:0.009861:0.005696:0.004240